3104NSC Chap.3 Screening, Hits and Lead Selection
Screening, Hits and Lead Selection
Define phenotypic screening
Screening, Hits and Lead Selection places phenotypic screening, target-based screening and hit-to-lead optimisation on a target-to-patient evidence chain.
The practical task is to choose a screening strategy and define the evidence needed to move from hit to lead; each step must connect the therapeutic need and biological target to molecular properties, ADME, exposure, effect and an appropriate formulation or delivery choice.
Place phenotypic screening at its correct stage in the development chain.
Define the evidential role of phenotypic screening — therapeutic need, target evidence, candidate property, exposure observation, effect measure, delivery constraint or synthesis claim — and separate what is measured from what remains inferred.
State whether target-based screening supplies a mechanism, comparison, prediction or evidence synthesis, then trace only the downstream molecular-property, ADME, exposure or effect changes it can support.
In Screening, Hits and Lead Selection, that distinction keeps target-based screening from being mistaken for a molecular mechanism when it instead names an assessment architecture, seminar or evidence dossier.
Use hit-to-lead optimisation as a discriminating test or control.
Specify which assay, pharmacokinetic observation, pharmacodynamic response, validation result or evidence-synthesis finding would support hit-to-lead optimisation, and name an alternative result that would weaken it.
For the application — choose a screening strategy and define the evidence needed to move from hit to lead — connect target evidence to a candidate, formulation or delivery choice without skipping the exposure-effect relationship.
Finish Screening, Hits and Lead Selection by stating which experiment or measurement should be run next and why its result could change the interpretation attached to hit-to-lead optimisation.
Build an evidence chain for phenotypic screening: therapeutic need and target; candidate property or interaction; ADME and exposure; observed effect; formulation or delivery constraint.
Place target-based screening and hit-to-lead optimisation at the step they actually test. A candidate described through phenotypic screening is not advanced merely because every stage can be named; the links to target-based screening and hit-to-lead optimisation require compatible evidence.
Trace target-based screening
Run a target-based screening counterfactual check.
Change one assumption or molecular property associated with target-based screening while holding the relevant target and dose conditions stable, then predict the direction of exposure and effect where that prediction is applicable.
Compare it with the hit-to-lead optimisation evidence; a mismatch between target-based screening and hit-to-lead optimisation may reveal an incorrect mechanism, missing evidence, off-target activity or a delivery limitation.
Rehearse Screening, Hits and Lead Selection from target to patient rather than as a list of terms.
Starting with phenotypic screening, state the target or therapeutic need, the property or evidence under study, the relevant ADME consequence, the exposure-effect observation and the formulation or delivery implication.
Mark the first unsupported transition between target-based screening and hit-to-lead optimisation, and repair it before adding another candidate claim.
A complete response should make the task visible before the detail: identify what must be decided, define the relevant terms, connect the evidence to target-based screening, and use hit-to-lead optimisation to test the result.
The final sentence about hit-to-lead optimisation should answer the question actually asked rather than merely repeat the topic.
The controlling limit is specific: Screen activity can reflect assay interference, toxicity or non-specific effects rather than useful target modulation.
Keep that hit-to-lead optimisation limit beside the worked example, because it separates a careful 3104NSC answer from one that sounds confident but claims more than the task or evidence supports.
For revision, retrieve phenotypic screening, target-based screening and hit-to-lead optimisation without notes, explain their relationship aloud, then complete a changed version of the application: choose a screening strategy and define the evidence needed to move from hit to lead.
Record the first failed target-based screening reasoning move and repair it before attempting another case.
What this chapter covers
- 01
phenotypic screening
- 02
target-based screening
- 03
hit-to-lead optimisation
- 04
Applying phenotypic screening
- 05
Limits of target-based screening and hit-to-lead optimisation
Worked example: Screening, Hits and Lead Selection
- 1Extract the outcome, actor or operation that the Screening, Hits and Lead Selection task actually requires.
- 1State the precondition under which phenotypic screening is relevant rather than merely familiar.
- 1Use target-based screening to reject the nearest alternative, then run a failure-path check with hit-to-lead optimisation.
- 1Choose the response and state when it must be withdrawn or narrowed: Screen activity can reflect assay interference, toxicity or non-specific effects rather than useful target modulation.
Key terms
- phenotypic screening
- Testing compounds for a desired cellular or organism-level effect without requiring a pre-specified molecular target. Use this definition when the task is to choose a screening strategy and define the evidence needed to move from hit to lead.
- target-based screening
- Testing compounds for activity against a defined biological target using a binding or functional assay. Use this definition when the task is to choose a screening strategy and define the evidence needed to move from hit to lead.
- hit-to-lead optimisation
- The iterative improvement of confirmed screening hits for potency, selectivity and developability before candidate selection. Use this definition when the task is to choose a screening strategy and define the evidence needed to move from hit to lead.
Screening, Hits and Lead Selection FAQ
What is the main task in Screening, Hits and Lead Selection?
Choose a screening strategy and define the evidence needed to move from hit to lead.
How do phenotypic screening and target-based screening work together?
Use phenotypic screening to establish the object or condition, then use target-based screening to explain how it changes the outcome being analysed.
What must a 3104NSC answer qualify here?
Screen activity can reflect assay interference, toxicity or non-specific effects rather than useful target modulation.
How should I revise Screening, Hits and Lead Selection?
Retrieve phenotypic screening, target-based screening and hit-to-lead optimisation, apply them to a changed case, and correct the first point where the evidence no longer supports the conclusion.
Assessment move
Reconstruct the relationship among phenotypic screening, target-based screening and hit-to-lead optimisation; complete the chapter application without notes; then test the result against this limit: Screen activity can reflect assay interference, toxicity or non-specific effects rather than useful target modulation.
Working through Screening, Hits and Lead Selection in 3104NSC? Sia is AskSia’s AI Biomedical Science tutor — ask any 3104NSC Screening, Hits and Lead Selection question and get a clear, step-by-step explanation grounded in how 3104NSC is taught and assessed. Read this chapter free, then take your hardest questions to Sia.
